Demonstrated that specific mutations affect activation profiles
Revealed potential for targeted therapies based on activation pathways
Abstract
Endometrial carcinoma (EC) is one of the most prevalent gynaecological malignancies found in women. About 10-12% of EC is caused due to mutations in Fibroblast Growth Factor Receptor 2 (FGFR2)....